Skip to main content Accessibility help
×
Home
Hostname: page-component-684899dbb8-ndjvl Total loading time: 0.275 Render date: 2022-05-18T14:01:18.226Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence

Published online by Cambridge University Press:  01 January 2021

Abstract

The FDA's new table of surrogate endpoints used for drug approvals is an important step forward for overseeing the use of biomarkers in clinical trials. Nevertheless, we present several ways in which the table can be improved.

Type
Symposium Articles
Copyright
Copyright © American Society of Law, Medicine and Ethics 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kesselheim, A. S. and Karlawish, J., “Biomarkers Unbound — The Supreme Court's Ruling on Diagnostic-Test Patents,” New England Journal of Medicine 366, no. 25 (2012): 2338-2340.CrossRefGoogle Scholar
Fleming, T. R. and DeMets, D. L., “Surrogate End Points in Clinical Trials: Are We Being Misled?” Annals of Internal Medicine 125, no. 7 (1996): 605-613.CrossRefGoogle Scholar
US Food and Drug Administration, “Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure,” available at <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm613636.htm> (last visited July 17, 2019).+(last+visited+July+17,+2019).>Google Scholar
Korn, E. L., Albert, P. S., and McShane, L. M., “Assessing Surrogates as Trial Endpoints Using Mixed Models,” Statistics in Medicine 24, no. 2 (2005): 163-182.CrossRefGoogle Scholar
Lipska, K. J. and Krumholz, H. M., “Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?” JAMA 317, no. 10 (2017): 1017-1018.CrossRefGoogle Scholar
Reddel, H. K., Taylor, D. R., Bateman, E. D., Boulet, L. P., Boushey, H. A., Busse, W. W., Casale, T. B., Chanez, P., Enright, P. L., Gibson, P. G., and de Jongste, J.C., “An official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice,” American Journal of Respiratory and Critical Care Medicine 180, no. 1 (2009): 59-99.CrossRefGoogle Scholar
Saldanha, I. J., Dickersin, K., Wang, X., and Li, T., “Outcomes in Cochrane Systematic Reviews Addressing Four Common Eye Conditions: An Evaluation of Completeness and Comparability,” PloS One 9, no. 10 (2014): e109400.CrossRefGoogle Scholar
1
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *